Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCMBHA)

Drug Name

Erlotinib Drug Info

Synonyms

Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-Quinazolinamine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline; 4-[(3-ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline

Indication

Disease Entry	ICD 11	Status	REF
Adrenal gland neoplasm		Approved	[1]
Adult hepatocellular carcinoma		Approved	[1]
Brain cancer	2A00	Approved	[1]
Esophageal disorder		Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[2]
Pancreatic adenocarcinoma		Approved	[1]
Psoriasis	EA90	Approved	[1]
Salivary gland squamous cell carcinoma		Approved	[1]
Pancreatic cancer	2C10	Phase 3	[2]
Colon cancer	2B90.Z	Phase 2	[2]
Ependymoma	2A00.0Y	Investigative	[1]
Neoplastic meningitis		Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID: 176870
ChEBI ID: CHEBI:114785
CAS Number: CAS 183321-74-6
TTD Drug ID: DMCMBHA
VARIDT Drug ID: DR00558
INTEDE Drug ID: DR0603
ACDINA Drug ID: D00239

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Epidermal growth factor receptor (EGFR)	TTGKNB4	EGFR_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	Highest Status	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Approved	[4]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Approved	[5]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	Highest Status	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Approved	[6]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Approved	[7]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Approved	[7]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Approved	[7]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Epidermal growth factor receptor (EGFR)	DTT	EGFR	6.045	4.991	5.317	5.252
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.009	6.988	7.442	8.135
Breast cancer resistance protein (ABCG2)	DTP	BCRP	6.732	7.513	6.326	9.277
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	10.036	5.779	6.508	6.481
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	10.08	7.207	5.403	9.211
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	3.307	5.005	3.921	5.327
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	11.692	6.58	4.984	9.089

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Adrenal gland neoplasm

ICD Disease Classification

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Epidermal growth factor receptor (EGFR)	DTT	EGFR	2.09E-05	0.4	190.08
Epidermal growth factor receptor (EGFR)	DTT	EGFR	6.32E-04	0.39	1.69
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.21E-01	-1.31E-01	-9.67E-02
Breast cancer resistance protein (ABCG2)	DTP	BCRP	9.24E-02	-8.49E-01	-5.22E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.80E-01	-3.78E-02	-2.75E+00
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	6.78E-06	-1.01E+00	-3.20E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	7.76E-01	-2.05E-01	-5.72E+00
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.78E-01	-1.22E-03	-4.10E-03
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.73E-01	-1.42E-01	-5.35E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	2.09E-09	-9.49E-01	-8.32E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	5.50E-01	-9.32E-02	-1.01E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.15E-08	-6.60E-01	-3.96E+00

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Erlotinib FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
3	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.
4	Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33.
5	Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.
6	In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
7	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.